PLIANT THERAPEUTICS INC. - COMMON STOCK

Pliant Therapeutics to Participate in Upcoming Investor Conferences

30 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

08 Aug 2022 16:05:02 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in BTIG Biotechnology Conference

02 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis

21 Jul 2022 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

15 Jul 2022 16:03:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Pricing of Upsized $200.0 Million Public Offering

12 Jul 2022 19:46:28 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Proposed Public Offering of Common Stock

11 Jul 2022 16:01:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

10 Jul 2022 18:10:21 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial

24 Jun 2022 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

22 Jun 2022 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

16 Jun 2022 08:00:02 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022

15 Jun 2022 16:01:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Presentations at 2022 American Thoracic Society International Conference

18 May 2022 11:15:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

11 May 2022 08:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

09 May 2022 16:05:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809

05 May 2022 08:00:03 By Nasdaq GlobeNewswire

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis

03 May 2022 08:00:02 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Multiple Presentations at the 2022 American Thoracic Society International Conference

02 May 2022 08:00:03 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Needham Healthcare Conference

05 Apr 2022 08:03:00 By Nasdaq GlobeNewswire

CORRECTION - Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

28 Feb 2022 19:43:43 By Nasdaq GlobeNewswire